Skip to main content
main-content

Latest news

Free registration

Medicine Matters was developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by


Editors' pick

17-05-2018 | Checkpoint blockade | News

Cancer immunotherapy efficacy may vary by sex

The magnitude of the survival benefit associated with immune checkpoint inhibitor treatment appears to be sex dependent, with women benefiting less than men, according to a meta-analysis published in The Lancet Oncology.

Source:

Lancet Oncol 2018; Advance online publication

Latest headlines

24-05-2018 | Mesothelioma | News

Tremelimumab plus durvalumab active in unresectable mesothelioma

Preliminary results suggest a role for the combination of the CTLA-4 inhibitor tremelimumab and the PD-L1 blocker durvalumab in the treatment of inoperable pleural or peritoneal mesothelioma.

23-05-2018 | Castration-resistant prostate cancer | News

[177Lu]-PSMA-617 shows promise for heavily pretreated mCRPC

Radionuclide treatment with lutetium-177-prostate-specific membrane antigen-617 shows potential for men with metastatic castration-resistant prostate cancer that has progressed after standard therapy, researchers report.

22-05-2018 | Gastric cancer | News

Breath test for esophagogastric cancer diagnosis validated

A noninvasive single breath test has potential for the diagnosis of esophagogastric cancer, say researchers.

In depth

27-04-2018 | Adolescents and young adults | Feature | Article

ACCELERATE-ing access to drugs for adolescents with cancer

medwireNews spoke to Miranda Fidler, from the International Agency for Research on Cancer, and Simon Davies, from Teen Cancer America, about the ACCELERATE working group's proposal to improve adolescent patients’ access to new cancer drugs.

Click for the accompanying news story

SUMIT: Selumetinib in metastatic uveal melanoma

This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

Expert comment: AMPLE trial

Listen to Fabien Maldonado, from Vanderbilt University Medical Center in Nashville, Tennessee, USA, give his views on the AMPLE trial, published in JAMA, which aimed to establish the more effective technique for reducing the number of hospitalization days in patients with malignant pleural effusion.

Conference highlights

10-09-2017 | Collection

medwireNews@ESMO 2017

We provide the latest research news, interviews, and much more from the ESMO 2017 Congress, in Madrid, Spain.

04-06-2017 | Collection

medwireNews@ASCO 2017

We provide coverage from the annual meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, USA. Click through for news stories, conference reports, interviews and more.

03-02-2017 | Collection

medwireNews@ASH 2016

News from annual meeting of the American Society of Hematology, held in San Diego, California, USA. Click through to read the full reports.

image credits